Deborah M. Autor net worth and biography

Deborah Autor Biography and Net Worth

Director of Amneal Pharmaceuticals

Deb Autor is CEO of Autor Strategies LLC, a strategic health care consulting firm; a Board Director for Pardes Biosciences, Inc. (PRDS); and Chair of the Board of the FDA Alumni Association. Ms. Autor has also served as a Scientific Advisory Council Member of the Centre for Innovation in Regulatory Science and as a Board Member of the Antimicrobial Resistance Industry Alliance, the United States Pharmacopoeia Quality Institute, and the Parenteral Drug Association.

From 2019-2021, Ms. Autor was Global Head of Regulatory Excellence at AstraZeneca, where she led regulatory operations, policy and intelligence for AstraZeneca submissions globally. Before joining AstraZeneca, Ms. Autor served at Mylan N.V. from 2013-2019, where she was Head of Strategic Global Quality and Regulatory Policy and Head of Global Quality.

Ms. Autor was a senior leader at FDA from 2001-2013, most recently as Deputy Commissioner for Global Regulatory Operations and Policy where she oversaw all FDA inspections, criminal investigations and international operations for human and veterinary drugs, biologics, medical devices, tobacco and food. Before that, Ms. Autor served as Director of the Office of Compliance of the Center for Drug Evaluation and Research, leading enforcement and policy making for compliance with all drug requirements, including drug approval; current good manufacturing practices (GMP); human subject protection and bioresearch monitoring (GCP); import and export; and recalls. Before joining FDA, Ms. Autor was a Trial Attorney in the Office of Consumer Litigation of the U.S. Department of Justice, where she litigated civil and criminal cases on behalf of FDA.

Ms. Autor received a Juris Doctor, Magna Cum Laude, from Boston University School of Law and a Bachelor of Arts in Psychology from Columbia University, Barnard College.

What is Deborah M. Autor's net worth?: The estimated net worth of Deborah M. Autor is at least $1.16 million as of May 11th, 2026. Autor owns 93,660 shares of Amneal Pharmaceuticals stock worth more than $1,160,447 as of May 13th. This net worth approximation does not reflect any other assets that Autor may own. Learn More about Deborah M. Autor's net worth.
How do I contact Deborah M. Autor?: The corporate mailing address for Autor and other Amneal Pharmaceuticals executives is 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807, United States. Amneal Pharmaceuticals can also be reached via phone at 908-947-3120 and via email at [email protected]. Learn More on Deborah M. Autor's contact information.
Has Deborah M. Autor been buying or selling shares of Amneal Pharmaceuticals?: During the past quarter, Deborah M. Autor has sold $450,557.86 of Amneal Pharmaceuticals stock. Most recently, Deborah M. Autor sold 34,819 shares of the business's stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a transaction totalling $450,557.86. Following the completion of the sale, the director now directly owns 93,660 shares of the company's stock, valued at $1,211,960.40. Learn More on Deborah M. Autor's trading history.
Who are Amneal Pharmaceuticals' active insiders?: Amneal Pharmaceuticals' insider roster includes Deborah Autor (Director), Andrew Boyer (EVP, Chief Commercial Officer – Generics), Jason Daly (SVP), John Kiely (Director), Ted Nark (Director), Chirag Patel (Co-Founder, Co-CEO, President & Director), Gautam Patel (Director), Nikita Shah (EVP), and Joseph Todisco (EVP). Learn More on Amneal Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amneal Pharmaceuticals?: During the last year, insiders at the sold shares 12 times. They sold a total of 875,881 shares worth more than $8,894,905.88. The most recent insider tranaction occured on May, 11th when Director Deborah M Autor sold 34,819 shares worth more than $450,557.86. Insiders at Amneal Pharmaceuticals own 17.3% of the company. Learn More about insider trades at Amneal Pharmaceuticals.
Information on this page was last updated on 5/11/2026.

Deborah M. Autor Insider Trading History at Amneal Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/11/2026	Sell	34,819	$12.94	$450,557.86	93,660

Deborah M. Autor Buying and Selling Activity at Amneal Pharmaceuticals

Amneal Pharmaceuticals Company Overview

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Today's Range

Now: $12.39

$12.34

$12.65

50 Day Range

MA: $12.73

$11.83

$13.91

2 Week Range

Now: $12.39

$7.02

$15.42

Volume

1,458,283 shs

Average Volume

2,279,538 shs

Market Capitalization

$3.90 billion

P/E Ratio

32.61

Dividend Yield

N/A

Beta

1.32